HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acne Relief In Brief

This article was originally published in The Rose Sheet

Executive Summary

Isolaz photopneumatic therapy: The "only painless laser treatment for acne" and the only system cleared by FDA to treat comedonal and postular acne, as well as mild to moderate acne (including acne vulgaris), Isolaz comes to aid of non-responders to traditional therapies -- whether topical, antibiotic or another laser -- and patients who had come to rely on Accutane, Aesthera Corporation suggests July 15. Drug maker Roche announced in June it was discontinuing distribution of Accutane (isotretinoin) due to increasing generic competition and the cost of product liability litigation, which have eaten into profits from what once was one of the company's top-selling products (1"The Pink Sheet" Daily, June 26, 2009). The move surprised some dermatologists and created concern that existing demand for isotretinoin could not be met, while Roche assured stakeholders that competing drug manufacturers would be able to supply the market. Regardless, "the bottom line is that physicians and patients need a viable alternative in their battle against acne," according to Aesthera CEO and President Alon Maor. In clinical testing Isolaz awarded immediate results within 24 to 48 hours and an 88% reduction in acne after four treatments without any of the side effects of systemic alternatives, the Pleasanton, Calif. firm says
Advertisement

Related Content

Roche Removes a Blemish: Drugmaker Drops Its One-Time Acne Blockbuster Accutane
Roche Removes a Blemish: Drugmaker Drops Its One-Time Acne Blockbuster Accutane
Advertisement
UsernamePublicRestriction

Register

RS016283

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel